Following the advisory committee's initial rejection, Capricor Therapeutics (CAPR) is in discussions with the FDA to revise the Biologics License Application (BLA) for deramiocel (developmental code CAP-1002), focusing on upper limb motor function. The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee voted 9-3 against the efficacy of deramiocel for DMD cardiomyopathy in its review on July 29, 2026. While this does not guarantee approval, it is not the FDA's final decision, and the revised application has not yet been submitted or accepted. The original PDUFA goal date of August 22 is subject to extension upon receipt of the substantial amendment, creating both short-term catalysts and regulatory uncertainties.

The basis for a potential re-submission lies in the data from the HOPE-3 trial. Deramiocel, prior to its brand name designation, is an allogeneic cardiosphere-derived cell therapy tested in a Phase 3 clinical trial. It aims to preserve skeletal and cardiac muscle function through immunomodulatory and anti-fibrotic pathways, rather than targeting a single molecule. The randomized, double-blind HOPE-3 trial enrolled 106 patients, with the deramiocel and placebo groups showing mean changes from baseline in the 12-month PUL 2.0 total score of -3.86% and -8.41%, respectively. The difference between the groups was 4.55 percentage points, or 1.2 points on the raw score, representing a 54% slowing of disease progression, with a p-value of 0.029. However, the FDA and the company have previously differed on statistical analysis plans and the interpretation of cardiac endpoints, so the positive Phase 3 results alone do not guarantee approval.

Focusing on upper limb function, which directly impacts eating, hygiene, and device use in later-stage DMD patients who have lost ambulation, could provide a more compelling argument for approval than cardiomyopathy. Competing standard treatments include corticosteroids such as Emflaza (deflazacort) and Agamree (vamorolone), as well as exon-skipping therapies for specific genetic mutations. Sarepta Therapeutics' (SRPT) Elevidys (delandistrogene moxeparvovec-rokl) received accelerated approval from the FDA on June 22, 2023. Deramiocel aims to differentiate itself as a repeat intravenous cell therapy, independent of genotype. The global DMD therapeutics market is projected to be in the range of USD 3.8 billion to USD 5.1 billion in 2026, representing a significant commercial opportunity, but safety, ease of administration, and label scope will determine market share.

The agreement with Nippon Shinyaku (TSE:4516) for exclusive U.S. distribution involves an upfront payment of USD 30 million and potential development and sales milestones of up to USD 705 million, totaling USD 735 million. Of this, USD 10 million was triggered by the futility analysis of HOPE-3 and the submission of the BLA, with an additional USD 80 million payable upon FDA approval and up to USD 605 million based on sales milestones. Capricor's share of product revenue will be 30-50%, and the ongoing litigation between the two companies regarding the U.S. distribution agreement represents a separate commercial risk. The 71% increase in the stock price reflects expectations that the development program is unlikely to be discontinued, but it is prudent to view this as a period of re-evaluation of approval probability until the revised application is accepted and a new PDUFA date is established.